Compare WYFI & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WYFI | ANNX |
|---|---|---|
| Founded | 2023 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 787.1M | 726.1M |
| IPO Year | 2025 | 2020 |
| Metric | WYFI | ANNX |
|---|---|---|
| Price | $9.62 | $3.70 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 10 |
| Target Price | ★ $40.45 | $17.00 |
| AVG Volume (30 Days) | 1.4M | ★ 3.4M |
| Earning Date | 11-12-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $79,164,252.00 | N/A |
| Revenue This Year | $76.12 | N/A |
| Revenue Next Year | $116.31 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 66.17 | N/A |
| 52 Week Low | $9.31 | $2.54 |
| 52 Week High | $46.87 | $7.18 |
| Indicator | WYFI | ANNX |
|---|---|---|
| Relative Strength Index (RSI) | 21.13 | 41.32 |
| Support Level | N/A | $3.36 |
| Resistance Level | $20.68 | $4.37 |
| Average True Range (ATR) | 0.97 | 0.24 |
| MACD | -0.34 | 0.02 |
| Stochastic Oscillator | 5.54 | 40.85 |
Whitefiber Inc is a provider of artificial intelligence infrastructure solutions. The company owns high-performance computing data centers and provide cloud-based HPC graphics processing units services, which it terms cloud services, for customers such as AI application and machine learning developers. Its Tier-3 data centers provide hosting and colocation services. Its cloud services support generative AI workstreams, especially training and inference. It has two reportable segments: cloud services and colocation services. The cloud services segment generates revenue from providing high performance computing services to support generative AI workstreams. Colocation services generate revenue by providing customers with physical space, power and cooling within the data center facility.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.